+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2020

  • ID: 4382655
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 60 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Asana BioSciences
  • Beta Pharma
  • Churchill Pharmaceuticals
  • Endo Pharmaceuticals
  • Solural Pharma
  • Tokai Pharmaceuticals
  • MORE
Overview

Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2020 report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Cytochrome P450 17 (CYP17) Inhibitor pipeline landscape is provided, which includes the topic overview and Cytochrome P450 17 (CYP17) Inhibitor mechanism of action.

The assessment part of the report embraces, in-depth Cytochrome P450 17 (CYP17) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Cytochrome P450 17 (CYP17) Inhibitor pipeline development activities

The report provides insights into:
  • All the companies developing therapies of Cytochrome P450 17 (CYP17) Inhibitor with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates in early-stage, mid-stage and late stage of development for Cytochrome P450 17 (CYP17) Inhibitor.
  • Key players involved in Cytochrome P450 17 (CYP17) Inhibitor targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details for future developments of Cytochrome P450 17 (CYP17) Inhibitor.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.

Cytochrome P450 17 (CYP17) Inhibitor Analytical Perspective

In-depth Cytochrome P450 17 (CYP17) Inhibitor Commercial Assessment of products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, acquisition deal value trends. The sub-segmentation is described in the report, which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.

Cytochrome P450 17 (CYP17) Inhibitor Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this mechanism of action.

Scope of the Report
  • The Cytochrome P450 17 (CYP17) Inhibitor report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Cytochrome P450 17 (CYP17) Inhibitor therapeutic products with key coverage of involved technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
  • Elucidated Cytochrome P450 17 (CYP17) Inhibitor research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Cytochrome P450 17 (CYP17) Inhibitor.
Report Highlights
  • In the coming years, the Cytochrome P450 17 (CYP17) Inhibitor market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Cytochrome P450 17 (CYP17) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • There are several companies involved in developing therapies for Cytochrome P450 17 (CYP17) Inhibitor. Launch of emerging therapies of Cytochrome P450 17 (CYP17) Inhibitor will significantly impact the market.
  • A better understanding of the target mechanism will also contribute to the development of novel therapeutics for Cytochrome P450 17 (CYP17) Inhibitor.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Cytochrome P450 17 (CYP17) Inhibitor) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions Answered
  • What are the current treatment options available based on the Cytochrome P450 17 (CYP17) Inhibitor?
  • How many companies are developing therapies by working on Cytochrome P450 17 (CYP17) Inhibitor?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for Cytochrome P450 17 (CYP17) Inhibitor to treat disease condition?
  • How many emerging therapies are in early-stage, mid-stage, and late stage of development for Cytochrome P450 17 (CYP17) Inhibitor?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cytochrome P450 17 (CYP17) Inhibitor therapies?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies developed based on this mechanism of action?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Cytochrome P450 17 (CYP17) Inhibitor and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Cytochrome P450 17 (CYP17) Inhibitor?
  • How many patents are granted and pending for the emerging therapies of Cytochrome P450 17 (CYP17) Inhibitor?

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Asana BioSciences
  • Beta Pharma
  • Churchill Pharmaceuticals
  • Endo Pharmaceuticals
  • Solural Pharma
  • Tokai Pharmaceuticals
  • MORE
1. Report Introduction

2. Cytochrome P450 17 (CYP17) Inhibitor
2.1. Cytochrome P450 17 (CYP17) Inhibitor Overview
2.2. Cytochrome P450 17 (CYP17) Inhibitor Classification
2.3. Cytochrome P450 17 (CYP17) Inhibitor Structure
2.4. Cytochrome P450 17 (CYP17) Inhibitor Mechanism of Action
2.5. Cytochrome P450 17 (CYP17) Inhibitor Application

3. Cytochrome P450 17 (CYP17) Inhibitor - Analytical Perspective
3.1. In-depth Commercial Assessment
3.1.1. Cytochrome P450 17 (CYP17) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
3.1.1.1. Assessment Summary
3.1.2. Cytochrome P450 17 (CYP17) Inhibitor Collaboration Deals
3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
3.1.2.3. Cytochrome P450 17 (CYP17) Inhibitor Acquisition Analysis

4. Therapeutic Assessment
4.1. Clinical Assessment of Pipeline Drugs
4.1.1. Assessment by Phase of Development
4.1.2. Assessment by Product Type (Mono/Combination)
4.1.2.1. Assessment by Stage and Product Type
4.1.3. Assessment by Route of Administration
4.1.3.1. Assessment by Stage and Route of Administration
4.1.4. Assessment by Molecule Type
4.1.4.1. Assessment by Stage and Molecule Type
4.1.5. Assessment by MOA
4.1.5.1. Assessment by Stage and MOA
4.1.6. Assessment by Target
4.1.6.1. Assessment by Stage and Target

5. Late Stage Products (Phase-III)

6. Mid Stage Products (Phase-II)

7. Early Stage Products (Phase-I)

8. Pre-clinical Products and Discovery Stage Products

9. Inactive Products

10. Dormant Products

11. Discontinued Products

12. Cytochrome P450 17 (CYP17) Inhibitor Product Profiles
12.1. Drug Name: Company
12.1.1. Product Description
12.1.1.1. Product Overview
12.1.1.2. Mechanism of action
12.1.2. Research and Development
12.1.2.1. Clinical Studies
12.1.3. Product Development Activities
12.1.3.1. Collaboration
12.1.3.2. Agreements
12.1.3.3. Acquisition
12.1.3.4. Patent Detail
12.1.4. Tabulated Product Summary
12.1.4.1. General Description Table
  • Detailed information in the report
13. Cytochrome P450 17 (CYP17) Inhibitor Key Companies

14. Cytochrome P450 17 (CYP17) Inhibitor Key Products

15. Dormant and Discontinued Products
15.1. Dormant Products
15.1.1. Reasons for being dormant
15.2. Discontinued Products
15.2.1. Reasons for the discontinuation

16. Cytochrome P450 17 (CYP17) Inhibitor - Unmet Needs

17. Cytochrome P450 17 (CYP17) Inhibitor - Future Perspectives

18. Cytochrome P450 17 (CYP17) Inhibitor Analyst Review

19. Appendix

20. Report Methodology
20.1. Secondary Research
20.2. Expert Panel Validation

List of Tables
Table 1: Assessment Summary
Table 2: Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3: Cytochrome P450 17 (CYP17) Inhibitor Acquisition Analysis
Table 4: Assessment by Phase of Development
Table 5: Assessment by Product Type (Mono/Combination)
Table 6: Assessment by Stage and Product Type
Table 7: Assessment by Route of Administration
Table 8: Assessment by Stage and Route of Administration
Table 9: Assessment by Molecule Type
Table 10: Assessment by Stage and Molecule Type
Table 11: Assessment by MOA
Table 12: Assessment by Stage and MOA
Table 13: Assessment by Target
Table 14: Assessment by Stage and Target
Table 15: Late Stage Products (Phase-III)
Table 16: Mid Stage Products (Phase-II)
Table 17: Early Stage Products (Phase-I)
Table 18: Pre-clinical and Discovery Stage Products
Table 19: Inactive Products
Table 20: Dormant Products
Table 21: Discontinued Products

List of Figures
Figure 1: Structure
Figure 2: Mechanism
Figure 3: Cytochrome P450 17 (CYP17) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
Figure 4: Company-Company Collaborations (Licensing/Partnering) Analysis
Figure 5: Cytochrome P450 17 (CYP17) Inhibitor Acquisition Analysis
Figure 6: Assessment by Phase of Development
Figure 7: Assessment by Product Type (Mono/Combination)
Figure 8: Assessment by Stage and Product Type
Figure 9: Assessment by Route of Administration
Figure 10: Assessment by Stage and Route of Administration
Figure 11: Assessment by Molecule Type
Figure 12: Assessment by Stage and Molecule Type
Figure 13: Assessment by MOA
Figure 14: Assessment by Stage and MOA
Figure 15: Late Stage Products (Phase-III)
Figure 16: Mid Stage Products (Phase-II)
Figure 17: Early Stage Products (Phase-I)
Figure 18: Pre-clinical and Discovery Stage Products
Figure 19: Inactive Products
Figure 20: Dormant Products
Figure 21: Discontinued Products
Figure 22: Unmet Needs
Note: Product cover images may vary from those shown
3 of 3
  • Churchill Pharmaceuticals
  • Asana BioSciences
  • Tokai Pharmaceuticals
  • Endo Pharmaceuticals
  • Beta Pharma
  • Solural Pharma
  • Viamet Pharmaceuticals
  • Mayssen Research & Development
Note: Product cover images may vary from those shown
Adroll
adroll